150TiP PYNNACLE phase II study of rezatapopt in patients with advanced solid tumors, including breast cancers, and a TP53 Y220C mutation

Journal article

Peer reviewed

J-S. Frenel, P. Zagami, G. Lopes, P. Grimison, M.L. Johnson, D.S. Tan, S. Kummar, K. Leduke, M. Fellous, E.E. Dumbrava, …

ESMO open, Vol.10

2025-05

Files and links (1)

url

https://doi.org/10.1016/j.esmoop.2025.104703View

Published (Version of record) Open

1 Record Views

Title: 150TiP PYNNACLE phase II study of rezatapopt in patients with advanced solid tumors, including breast cancers, and a TP53 Y220C mutation
Creators: J-S. Frenel - Institut de Cancérologie de l'Ouest
P. Zagami - Oncology Department, IEO - Istituto Europeo di Oncologia IRCCS, Milan, Italy
G. Lopes - Sylvester Comprehensive Cancer Center
P. Grimison - Chris O’Brien Lifehouse
M.L. Johnson - Sarah Cannon Research Institute
D.S. Tan - Department of Medical Oncology, NUHS - National University Health System, Singapore
S. Kummar - OHSU Knight Cancer Institute
K. Leduke - PMV Pharmaceuticals, PMV Pharmaceuticals, Cranbury, United States of America
M. Fellous - Medical Affairs/Oncology Dept, PMV Pharmaceuticals, Cranbury, United States of America
E.E. Dumbrava - The University of Texas MD Anderson Cancer Center
A. Schram - Memorial Sloan Kettering Cancer Center
Publication Details: ESMO open, Vol.10
Publisher: Elsevier Ltd
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
Record Identifier: 991032665524302976